3SBio Inc (83B) - Total Assets
Based on the latest financial reports, 3SBio Inc (83B) holds total assets worth €23.83 Billion EUR (≈ $27.86 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 3SBio Inc book value and equity for net asset value and shareholders' equity analysis.
3SBio Inc - Total Assets Trend (2016–2024)
This chart illustrates how 3SBio Inc's total assets have evolved over time, based on quarterly financial data.
3SBio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
3SBio Inc's total assets of €23.83 Billion consist of 38.6% current assets and 61.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.4% |
| Accounts Receivable | €1.26 Billion | 5.2% |
| Inventory | €795.19 Million | 3.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.68 Billion | 7.0% |
| Goodwill | €4.25 Billion | 17.6% |
Asset Composition Trend (2016–2024)
This chart illustrates how 3SBio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 3SBio Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 3SBio Inc's current assets represent 38.6% of total assets in 2024, an increase from 20.3% in 2016.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2024, up from 6.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, a decrease from 57.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 17.6% of total assets.
3SBio Inc Competitors by Total Assets
Key competitors of 3SBio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merus BV
NASDAQ:MRUS
|
USA | $771.99 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Savara Inc
NASDAQ:SVRA
|
USA | $140.92 Million |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥2.96 Billion |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
3SBio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.34 | 1.72 | 4.16 |
| Quick Ratio | 2.12 | 1.57 | 3.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.63 Billion | €3.85 Billion | €5.22 Billion |
3SBio Inc - Advanced Valuation Insights
This section examines the relationship between 3SBio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.17 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 2.5% |
| Total Assets | €24.21 Billion |
| Market Capitalization | $5.88 Billion USD |
Valuation Analysis
Below Book Valuation: The market values 3SBio Inc's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: 3SBio Inc's assets grew by 2.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for 3SBio Inc (2016–2024)
The table below shows the annual total assets of 3SBio Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €24.21 Billion ≈ $28.31 Billion |
+2.49% |
| 2023-12-31 | €23.63 Billion ≈ $27.62 Billion |
+7.44% |
| 2022-12-31 | €21.99 Billion ≈ $25.71 Billion |
+14.45% |
| 2021-12-31 | €19.21 Billion ≈ $22.46 Billion |
+8.68% |
| 2020-12-31 | €17.68 Billion ≈ $20.67 Billion |
+19.37% |
| 2019-12-31 | €14.81 Billion ≈ $17.31 Billion |
+7.01% |
| 2018-12-31 | €13.84 Billion ≈ $16.18 Billion |
+0.63% |
| 2017-12-31 | €13.75 Billion ≈ $16.08 Billion |
+24.59% |
| 2016-12-31 | €11.04 Billion ≈ $12.91 Billion |
-- |
About 3SBio Inc
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER… Read more